Known targets — ChEMBL curated mechanism
GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQ
The experimentally established mechanism targets of Estazolam. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 known ✓ | P14867 | 2/20 | 0.62 |
| ▸ | GABRA5 known ✓ | P31644 | 2/20 | 0.62 |
| ▸ | GABRA3 known ✓ | P34903 | 2/20 | 0.62 |
| ▸ | GABRA2 known ✓ | P47869 | 2/20 | 0.62 |
| ▸ | GABRB2 known ✓ | P47870 | 2/20 | 0.62 |
| ▸ | GABRP known ✓ | O00591 | 1/20 | 0.56 |
| ▸ | GABRD known ✓ | O14764 | 1/20 | 0.56 |
| ▸ | GABRB1 known ✓ | P18505 | 1/20 | 0.56 |
| ▸ | GABRG2 known ✓ | P18507 | 1/20 | 0.56 |
| ▸ | GABRB3 known ✓ | P28472 | 1/20 | 0.56 |
| ▸ | GABRA4 known ✓ | P48169 | 1/20 | 0.56 |
| ▸ | GABRE known ✓ | P78334 | 1/20 | 0.56 |
| ▸ | GABRA6 known ✓ | Q16445 | 1/20 | 0.56 |
| ▸ | GABRG1 known ✓ | Q8N1C3 | 1/20 | 0.56 |
| ▸ | GABRG3 known ✓ | Q99928 | 1/20 | 0.56 |
| ▸ | GABRQ known ✓ | Q9UN88 | 1/20 | 0.56 |
| ▸ | OPRK1 | P41145 | 6/20 | 1.00 |
| ▸ | PDE4D | Q08499 | 2/20 | 1.00 |
| ▸ | HPGD | P15428 | 3/20 | 0.62 |
| ▸ | BRD4 | O60885 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Estazolam SCHEMBL29357458 | 1.00 | OPRK1 (1.00) | OPRK1PDE4DHPGDGABRA1GABRA5 | |
| Estazolam SCHEMBL21225210 | 0.89 | OPRK1 (0.80) | OPRK1PDE4DHPGDGABRA1GABRA5 | |
| Alprazolam SCHEMBL4973049 | 0.89 | GABRA1 (0.82) | OPRK1PDE4DHPGDGABRA1GABRA5 | |
| SCHEMBL11836702 | 0.88 | OPRK1 (0.78) | OPRK1PDE4DHPGDGABRA1GABRA5 | |
| SCHEMBL11836695 | 0.88 | OPRK1 (0.78) | OPRK1PDE4DHPGDGABRA1GABRA5 | |
| SCHEMBL7435143 | 0.86 | OPRK1 (0.76) | OPRK1PDE4DHPGDGABRA1GABRA5 | |
| SCHEMBL11108528 | 0.85 | OPRK1 (0.74) | OPRK1PDE4DHPGDGABRA1GABRA5 | |
| SCHEMBL11639409 | 0.85 | OPRK1 (0.73) | OPRK1PDE4DHPGDGABRA1GABRA5 | |
| Pinazepam SCHEMBL6130050 | 0.84 | OPRK1 (0.71) | OPRK1PDE4DHPGDGABRA1GABRA5 | |
| Triazolam SCHEMBL28086118 | 0.84 | GABRA1 (0.75) | OPRK1PDE4DHPGDGABRA1GABRA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 13291 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12624037-B2 | Method of treating agitation, aggressive behavior, and impulse control disorder | INTRA-CELLULAR THERAPIES, INC. (US) | 2026-05-12 | — | — | US | claimed |
| US-12624036-B2 | Method of treating post-traumatic stress disorder | INTRA-CELLULAR THERAPIES, INC. (US) | 2026-05-12 | — | — | US | claimed |
| WO-2026090360-A1 | FUSED PYRIMIDINE COMPOUNDS FOR TREATMENT OF TINNITUS, HEARING LOSS, AND MENIERE'S DISEASE | OVID THERAPEUTICS INC. (US) | 2026-04-30 | — | — | WO | claimed |
| US-20260108529-A1 | FUSED AMINO PYRIMIDINE COMPOUNDS FOR TREATMENT OF TINNITUS, ACUTE SENSORINEURAL HEARING LOSS, AGE-RELATED HEARING LOSS, AND MENIERE'S DISEASE | OVID THERAPEUTICS INC (US) | 2026-04-23 | — | — | US | claimed |
| EP-4727627-A1 | AEROSOL-GENERATING DEVICE WITH IMPROVED AIRFLOW | Alexza Pharmaceuticals, Inc. (US) | 2026-04-22 | — | — | EP | claimed |
| EP-4719552-A1 | INDUCTION OF GENERAL ANESTHESIA IN ADULTS UNDERGOING ELECTIVE SURGERY | Xizang Haisco Pharmaceutical Co., Ltd. (CN) | 2026-04-08 | — | — | EP | claimed |
| US-20260076953-A1 | METHODS OF DIAGNOSING AND TREATING ADHD IN BIOMARKER POSITIVE SUBJECTS | THE CHILDREN'S HOSPITAL OF PHILADELPHIA (US) | 2026-03-19 | — | — | US | claimed |
| EP-3507371-B1 | COMPOSITIONS FOR TREATING DISEASES AND DISORDERS OF THE NERVOUS SYSTEM | UNIV RUTGERS (US) | 2026-01-28 | — | — | EP | claimed |
| US-20250375421-A1 | METHODS OF USING DMT | SHULMAN WILLIAM (US) | 2025-12-11 | — | — | US | claimed |
| EP-3746138-B1 | ELECTRICAL CONDENSATION AEROSOL DEVICE | ALEXZA PHARMACEUTICALS INC (US) | 2025-12-10 | — | — | EP | claimed |
| EP-0139460-A2 | Benzodiazepines and their therapeutic use | THE UPJOHN COMPANY (US) | 1985-05-02 | — | — | EP | claimed |
| US-4501698-A | REACTION WITH PARAFORMALDEHYDE, SULFONYL HALIDE, AMINO COMPOUND | THE UPJOHN COMPANY (US) | 1985-02-26 | — | — | US | claimed |
| EP-0127417-A1 | Process for preparing 1-dimethylaminomethyl-triazolobenzodiazepines | THE UPJOHN COMPANY (US) | 1984-12-05 | — | — | EP | claimed |
| US-4481208-A | Treatment of panic disorders with estazolam | THE UPJOHN COMPANY (US) | 1984-11-06 | — | — | US | claimed |
| EP-0121375-A1 | Processes for preparing 1-(hydroxymethyl)triazolobenzodiazepines and 1-(aminomethyl)triazolobenzodiazepines | THE UPJOHN COMPANY (US) | 1984-10-10 | — | — | EP | claimed |
| US-4474699-A | Preparing 1-aminomethyl-6-substituted-4H-s-triazolo[4,3-a][1,4]benzodiazepines in improved procedures | THE UPJOHN COMPANY (US) | 1984-10-02 | — | — | US | claimed |
| EP-0104053-A1 | Benzodiazepines for treating panic disorders | THE UPJOHN COMPANY (US) | 1984-03-28 | — | — | EP | claimed |
| EP-0050487-A1 | Pharmaceutical compositions comprising a benzodiazepine drug and a phenanthridine derivative | PFIZER INC. (US) | 1982-04-28 | — | — | EP | claimed |
| US-4320124-A | ANALGESICS | PFIZER INC. (US) | 1982-03-16 | — | — | US | claimed |
| US-3987052-A | SEDATIVES, TRANQUILIZERS, MUSCLE RELAXANTS | THE UPJOHN COMPANY (US) | 1976-10-19 | — | — | US | claimed |